KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Get a grip! - Baseline handgrip strength and sarcopenia as predictors of survival in patients with head and neck squamous cell carcinoma. PMID 42069057 · Clin Nutr ESPEN · 2026-Jun The record describes an observational sub-study of a randomized trial. The parent trial's intervention is described as a 'randomized nutritional intervention', and the sub-study analyzes associations of baseline HGS/sarcopenia with survival. While it is oncology, human, randomized, and reports time-to-event efficacy (OS with HR and KM), it does not meet the requirement of a drug-containing intervention. The phase is not explicitly stated in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women - Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study. PMID 42068869 · Maturitas · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identifying Symptom Clusters for Acute Dermatitis-Exploratory Analysis of a Randomized Control Trial Comparing Mepitel Film and Standard of Care for the Prevention of Radiation Dermatitis. PMID 42066679 · Clin Breast Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA). PMID 42058637 · ESMO Gastrointest Oncol · 2026-Jun This is a protocol/design description for an ongoing open-label, non-randomized Phase Ib/II platform trial. It does not report results of a randomized trial, is not Phase III, and lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) in the abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of selpercatinib as a first-line treatment for RET-fusion positive non-small-cell lung cancer: a novel two-stage Bayesian network meta-analysis. PMID 42052748 · J Comp Eff Res · 2026-Jun The record is a network meta-analysis that uses data from single-arm and other trials to model comparative effectiveness. It is not an original, formal-result report of a randomized, controlled trial with a drug-containing intervention and a primary time-to-event endpoint. The publication types include Phase I/II, and the study is not a definitive trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mapping the mRS Into the EQ-5D-5L in Patients With Ischemic Stroke. PMID 42052683 · Stroke · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of gradient compression sleeves in preventing postoperative upper extremity lymphoedema after breast cancer surgery. PMID 42051193 · Expert Rev Med Devices · 2026-Jun The study is an oncology randomized controlled trial evaluating a medical device (compression sleeves) for preventing lymphedema after breast cancer surgery. It lacks a drug intervention and a primary time-to-event efficacy endpoint (e.g., survival, progression).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial. PMID 42044642 · Lancet Neurol · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. PMID 42036072 · Diabetes Res Clin Pract · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial. PMID 42032072 · Nat Med · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Virtual health coaching to improve self-care among informal caregivers of hospitalized older adults during a transition in care: Randomized controlled trial study protocol. PMID 42031229 · Contemp Clin Trials · 2026-Jun 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors. PMID 42026180 · Leukemia · 2026-Jun The study is a non-comparative Phase IIIb trial in oncology (CML-CP) with a drug intervention (asciminib), but it is not randomized and its primary efficacy endpoint is a binary response rate (MMR rate), not a time-to-event outcome like OS, PFS, or DFS. No Kaplan-Meier or HR for such an endpoint is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. PMID 42009015 · Lancet Diabetes Endocrinol · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study. PMID 42006557 · Bone Rep · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia. PMID 42002452 · Clin Lymphoma Myeloma Leuk · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial. PMID 42001583 · Oral Oncol · 2026-Jun The record describes a supplementary analysis of a Phase II/III randomized trial, but it is a secondary analysis focused on toxicity risk factors (aspiration pneumonia), not a primary or key secondary efficacy report for a drug intervention. The drug intervention itself is not explicitly detailed in the abstract.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. PMID 41997804 · Ann Rheum Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised Prostate Cancer. PMID 41996829 · Clin Oncol (R Coll Radiol) · 2026-Jun The study is an eligible Phase III RCT in human oncology with primary time-to-event endpoints, but it does not meet the required drug-containing intervention criterion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations. PMID 41995421 · J Parkinsons Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H L
旧查询独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01). PMID 41991754 · J Gastroenterol · 2026-Jun The record describes an exploratory analysis of a randomized trial (JASPAC-01) focused on a dosage formula's relationship to adverse events and dose reduction. While the trial itself is oncology, human, randomized, involves a drug intervention (S-1), and includes a time-to-event outcome (5-year overall survival), this specific report is not a primary or key secondary efficacy analysis of the trial. It is a secondary, post-hoc, or safety-focused analysis, which is excluded per the criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia in Denmark: an open-label, randomised controlled trial. PMID 41990768 · Lancet Child Adolesc Health · 2026-Jun The record is an original RCT in oncology patients, but it is ineligible due to lack of a drug-containing intervention (it compares durations of existing antibiotic therapy, not a novel drug vs. control) and absence of a primary time-to-event efficacy endpoint (OS, PFS, etc.) with KM or HR reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Pilot Randomized Cross-Over Trial Focused on Colonoscopy Skill Acquisition Using High Fidelity Versus Low Fidelity Simulators in Nigeria. PMID 41990515 · J Surg Educ · 2026-Jun This is a pilot randomized crossover trial comparing colonoscopy simulation training methods (high-fidelity vs. low-fidelity) in a medical education context. While it mentions colorectal cancer as background, the study itself is not a therapeutic intervention trial for cancer, does not involve a drug, is not Phase III, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curve).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. PMID 41990460 · Semin Arthritis Rheum · 2026-Jun This is an observational study (target trial emulation using Medicare data) comparing antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. It is not an oncology study, not a randomized trial, and does not report on a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III randomized drug trial for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trial. PMID 41990428 · Contemp Clin Trials · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial. PMID 41989666 · Int J Clin Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial. PMID 41986965 · Cancer Sci · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial. PMID 41986167 · Clin Lymphoma Myeloma Leuk · 2026-Jun The record describes a Phase III randomized trial in Hodgkin lymphoma with drug interventions, but the reported endpoints are patient-reported outcomes for chemotherapy-induced peripheral neuropathy and quality of life. No time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR for survival) is reported. Therefore, it does not meet the key criterion for inclusion in the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. PMID 41978554 · Br J Haematol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France. PMID 41973335 · Drugs Real World Outcomes · 2026-Jun The record describes a real-world descriptive analysis of an early access program for olaparib combination therapy in prostate cancer. While it mentions the PROpel Phase III trial as the basis for approval, it does not report the results of that trial. The study itself is non-randomized, does not present time-to-event efficacy endpoints, and is not an original report of a randomized trial result.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes. PMID 41967586 · Fr J Urol · 2026-Jun The record describes a Phase II randomized trial, not a Phase III or IIIb trial as required. Although it meets other criteria (oncology, human, randomized, time-to-event endpoint, drug intervention), the phase is insufficient for eligibility.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). PMID 41962116 · J Clin Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Promising efficacy of coenzyme Q10 supplementation as adjunctive therapy in juvenile idiopathic arthritis: a randomized-controlled pilot study. PMID 41958203 · Immunopharmacol Immunotoxicol · 2026-Jun This record is an original randomized controlled trial (Phase II/III) in humans, but it fails multiple key eligibility criteria: 1) It is not an oncology/malignant neoplasm study (juvenile idiopathic arthritis). 2) The intervention is a dietary supplement (CoQ10), not a drug. 3) The primary efficacy endpoint is a disease activity score (JADAS-10), not a time-to-event endpoint like OS, PFS, etc. No Kaplan-Meier or HR is reported. Therefore, it is ineligible.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. PMID 41958186 · J Child Adolesc Psychopharmacol · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. PMID 41957135 · Br J Cancer · 2026-Jun The record describes a secondary analysis of individual patient data from multiple randomized phase II/III trials of concurrent chemoradiotherapy (cCRT) for NSCLC. While it includes oncology, human subjects, randomized trials, phase III/IIIb studies, and time-to-event endpoints (PFS, OS), the drug intervention is not explicitly established as a defining factor of the analysis (cCRT is a regimen, but the specific drug intervention is not detailed or contrasted with a non-drug control). Furthermore, this is a pooled analysis of multiple trials, not the primary result report of a single randomized trial, making it a secondary analysis rather than the original definitive report required.
S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of scalp cooling system versus chemical cooling cap in preventing chemotherapy-induced alopecia in breast cancer (COHAIR Study): a prospective randomized trial. PMID 41955993 · Breast · 2026-Jun The trial is a randomized, prospective study in oncology patients, but its primary efficacy endpoint is the prevention of chemotherapy-induced alopecia (a supportive care outcome), not a key time-to-event efficacy endpoint (like OS, PFS, DFS) for the cancer itself. The mention of DFS as comparable is incidental and not the primary focus. The trial phase is not confirmed to be Phase III or definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. PMID 41954860 · Adv Ther · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial. PMID 41953358 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Neoadjuvant chemotherapy for obstructive colon cancer derived by a stoma: Study protocol of the FRENCH-01 randomized phase III trial (COnCERTO Trial). PMID 41945039 · Dig Liver Dis · 2026-Jun 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 41944053 · J Child Adolesc Psychopharmacol · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aficamten: First Approval. PMID 41941083 · Drugs · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Protocol summary and statistical analysis plan for the bone loss prevention with zoledronic acid or denosumab in critically ill adults (BONE ZONE) trial. PMID 41940313 · Crit Care Resusc · 2026-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
STRASS 2 target trial emulation: Bridging the gap between trial efficacy and real-world effectiveness. PMID 41936769 · Surgery · 2026-Jun The record is a target trial emulation study using real-world data to evaluate the STRASS 2 trial's concept. It is not the original report of a Phase III/IIIb or Phase II/III randomized clinical trial. The study itself is observational and retrospective, not a prospective randomized trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis. PMID 41936548 · Obesity (Silver Spring) · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review. PMID 41935608 · J Gastrointest Surg · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Recombinant human hyaluronidase PH20 facilitates rapid subcutaneous infusion: two randomized, double-blind, self-controlled phase III clinical trials. PMID 41935547 · Eur J Pharm Biopharm · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. PMID 41934464 · J Thorac Oncol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial. PMID 41932350 · Lancet Gastroenterol Hepatol · 2026-Jun The trial is a Phase 3 randomized oncology trial with a primary OS endpoint and HR, but it compares two surgical techniques (robot-assisted vs. conventional minimally invasive esophagectomy). It lacks a drug-containing intervention as required for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC. PMID 41930542 · Lung Cancer · 2026-Jun This is a feasibility study for a potential future Phase III trial, not a definitive efficacy trial. The intervention is surgical vs non-surgical multimodality treatment, with no drug-containing arm. The primary outcomes are feasibility metrics (recruitment, adherence, HRQoL completion), not time-to-event efficacy endpoints like OS or PFS.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial. PMID 41922627 · Clin Rheumatol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. PMID 41917160 · Nat Med · 2026-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -